Royal Bank of Canada
SLS icon

Royal Bank of Canada’s SELLAS Life Sciences SLS Stock Holding History

Royal Bank of Canada’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Sell
4,171
-3,480
-45% -$15.6K ﹤0.01% 5952
2025
Q4 		$29K Sell
7,651
-1,794
-19% -$3.49K ﹤0.01% 5850
2025
Q3 		$14K Buy
9,445
+6,871
+267% +$12.2K ﹤0.01% 6369
2025
Q2 		$5K Sell
2,574
-10,551
-80% -$16.2K ﹤0.01% 6654
2025
Q1 		$14K Buy
13,125
+12,925
+6,463% +$15.3K ﹤0.01% 6047
2024
Q4 		$0 Hold
200
– – ﹤0.01% 7221
2024
Q3 		$0 Sell
200
-469
-70% -$573 ﹤0.01% 7385
2024
Q2 		$1K Buy
669
+446
+200% +$607 ﹤0.01% 6893
2024
Q1 		$0 Sell
223
-135
-38% -$113 ﹤0.01% 7539
2023
Q4 		$0 Buy
358
+158
+79% +$171 ﹤0.01% 7536
2023
Q3 		$0 Sell
200
-191
-49% -$301 ﹤0.01% 7532
2023
Q2 		$0 Buy
391
+191
+96% +$307 ﹤0.01% 7632
2023
Q1 		$0 Hold
200
– – ﹤0.01% 7430
2022
Q4 		$0 Sell
200
-126
-39% -$353 ﹤0.01% 7666
2022
Q3 		$0 Buy
326
+126
+63% +$348 ﹤0.01% 7814
2022
Q2 		$0 Sell
200
-300
-60% -$879 ﹤0.01% 7683
2022
Q1 		$3K Hold
500
– – ﹤0.01% 7398
2021
Q4 		$3K Hold
500
– – ﹤0.01% 7346
2021
Q3 		$5K Buy
500
+100
+25% +$928 ﹤0.01% 7143
2021
Q2 		$4K Buy
+400
New +$3.9K ﹤0.01% 7131
2021
Q1 		– Sell
-3,300
Closed -$19K – 7660
2020
Q4 		$19K Buy
+3,300
New +$13.2K ﹤0.01% 6092
2018
Q1 		– Sell
-1
Closed -$1K – 6749
2017
Q4 		$1K Buy
+1
New +$484 ﹤0.01% 6417
2017
Q3 		– Hold
0
– – – 6953
2017
Q2 		– Sell
-1
Closed -$870 – 6745
2017
Q1 		$1K Buy
+1
New +$1.66K ﹤0.01% 6524
2016
Q4 		– Hold
0
– – – 6564

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Royal Bank of Canada's SLS Position: Q1 2026 in Review

Royal Bank of Canada reduced its SELLAS Life Sciences (SLS) stake by 45% in Q1 2026, selling an estimated $15.6K and leaving 4,171 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #5952.

Royal Bank of Canada first reported a position in SLS in Q1 2017 and has held it in 23 quarters since. The position peaked at $29K in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Royal Bank of Canada held 4,171 shares of SELLAS Life Sciences worth $18K as of Q1 2026.
  • Royal Bank of Canada sold 3,480 SELLAS Life Sciences shares in Q1 2026, an estimated $15.6K.
  • SELLAS Life Sciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5952 holding.
  • Royal Bank of Canada first reported a position in SELLAS Life Sciences in Q1 2017 and has held it in 23 quarters since.
  • Royal Bank of Canada's SELLAS Life Sciences position peaked at $29K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.